This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: The University of Toledo, Medical College of Ohio. Active years: 1997-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1997-2012
Title: Jerzy Jankun: Innovator in Modified Plasminogen Activator Inhibitor Research
Introduction
Jerzy Jankun is a notable inventor based in Sylvania, OH (US), recognized for his contributions to the field of biochemistry and pharmaceuticals. He holds a total of 3 patents, focusing on modified plasminogen activator inhibitors and their therapeutic applications. His work has significant implications for treating various medical conditions associated with angiogenesis and cardiovascular diseases.
Latest Patents
Jankun's latest patents include innovative methods and compositions related to modified plasminogen activator inhibitor type-1 (PAI-1) molecules. One of his inventions describes a modified PAI-1 molecule that exhibits an increased in vivo half-life while being deficient in certain functional activities compared to the wild-type PAI-1 protein. This modified molecule has potential applications in pharmaceutical compositions aimed at treating conditions such as psoriasis, chronic inflammation, and tumor invasion. Another patent focuses on the discovery that modified PAI-1, where specific amino acid residues are replaced to form intramolecular disulfide bonds, also shows an increased half-life. This invention opens avenues for therapeutics targeting cardiovascular diseases related to hyperfibrinolysis and vessel leakage syndrome.
Career Highlights
Throughout his career, Jerzy Jankun has worked with esteemed institutions such as the University of Toledo and the Medical College of Ohio. His research has contributed to advancements in understanding the role of PAI-1 in various pathological conditions, enhancing the potential for innovative treatments.
Collaborations
Jankun has collaborated with notable colleagues, including Ewa Skrzypczak-Jankun and Steven H Selman, further enriching his research endeavors and expanding the impact of his work in the scientific community.
Conclusion
Jerzy Jankun's innovative research in modified plasminogen activator inhibitors has paved the way for new therapeutic strategies in treating critical health conditions. His contributions continue to influence the fields of biochemistry and pharmaceuticals, showcasing the importance of innovation in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile